ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 831

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab (AMG 827) in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Karel Pavelka1, Yun Chon2, Richard Newmark2, Ngozi Erondu3 and Shao- Lee Lin2, 1Institute of Rheumatology and Department of Rheumatology, 1st Medical Faculty, Charles University Prague, Prague, Czech Republic, 2Clinical Development, Amgen Inc, Thousand Oaks, CA, 3Amgen Inc, Thousand Oaks, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: clinical trials, interleukins (IL) and rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities

Session Type: Abstract Submissions (ACR)

Background/Purpose: A potential role for IL-17 in rheumatoid arthritis (RA) has been supported by data from clinical studies of inhibitors of the IL-17A ligand. To evaluate efficacy and safety of brodalumab (AMG 827), a human monoclonal antibody inhibitor of the IL-17 Receptor, in subjects with RA.

Methods: Subjects with RA who had an inadequate response to methotrexate (ie, continuing RA symptoms) and were biologic-naïve were randomized 1:1:1:1 to receive brodalumab (70, 140, or 210 mg) or placebo subcutaneously at day 1 and weeks 1, 2, 4, 6, 8, and 10 (Q2WK). Primary endpoint was proportion of subjects achieving an American College of Rheumatology (ACR) 50 response at week 12. Secondary endpoints included proportion with ACR 20 and 70 at week 12 and Disease Activity Score 28 joint (DAS28) at week 12. Safety was assessed by monitoring adverse events (AEs). Analyses were based on intent to treat using non-responder imputation.

Results: Two hundred fifty-two subjects were randomized; 189 to brodalumab and 63 to placebo. Two hundred forty-two subjects (183 [97%] AMG 827; 59 [94%] placebo) completed the study (defined as 16 weeks of study evaluations). Demographics and baseline characteristics were generally balanced among treatment groups. The majority (> 75%) of subjects were female and white. In subjects treated with brodalumab and placebo, respectively, mean (SD) age was 50.6 (11.5) years and 53.3 (10.3) years, mean weight was 72.8 (15.1) kg and 74.8 (16.5) kg, mean duration of RA was 8.1 (7.9) years and 7.5 (6.9) years, mean Disease Activity Score 28 joint (DAS28) was 6.5 (0.8) and 6.4 (0.8), and mean C-reactive protein (CRP) was 12.8 (12.1) mg/L and 14.6 (17.6) mg/L.

ACR 50 at week 12 occurred in 16% (70 mg), 16% (140 mg), 10% (210 mg), and 13% (placebo; all non-significant vs placebo) of subjects. Differences in ACR 20 and 70 were non-significant (p > 0.05) for any treatment group as compared with placebo. Mean (SD) change from baseline in DAS28 at week 12 was -1.4 (1.3) , ‑1.3 (1.2) , -1.3 (1.2) , and -1.3 (1.2) for the 70 mg, 140 mg, 210 mg and placebo groups, respectively. The p-values for DAS28 at week 12 in brodalumab treatment groups compared with placebo were all non-significant (p > 0.05). Mean (SD) percent CRP change was 97.5 (345.4), 50.7 (168.7) , 45.1 (159.3) , and 33.5 (170.3) for the 70 mg, 140 mg, 210 mg and placebo groups, respectively. No differences in efficacy outcomes for subgroup analyses based on sex, age, weight, or region were observed. Incidences of all AEs, including serious AEs (SAEs), were similar across treatment groups. A total of 7 subjects reported SAEs during the study (2 in the placebo group and 5 in the brodalumab groups), none of which was treatment related. There was 1 death (cardiopulmonary failure) ~1 week after last dose in the 140 mg group.

Conclusion: There was no evidence of meaningful clinical efficacy or change in CRP with brodalumab treatment in subjects with RA who had an inadequate response to methotrexate. Short-term treatment was well tolerated across a dose range of 70 to 210 mg and these analyses did not suggest any safety risks with brodalumab administration. These preliminary results do not support further evaluation of brodalumab as a treatment for RA.


Disclosure:

K. Pavelka,

Amgen Inc,

8,

Roche Pharmaceuticals,

8,

Abbott Laboratories,

8,

Pfizer Inc,

8,

Merck Sharp & Dohme Corp,

8;

Y. Chon,

Amgen Inc,

1,

Amgen Inc,

3;

R. Newmark,

Amgen Inc,

1,

Amgen Inc,

3;

N. Erondu,

Amgen Inc,

1,

Amgen Inc,

3;

S. L. Lin,

Amgen Inc,

1,

Amgen Inc,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-randomized-double-blind-placebo-controlled-multiple-dose-study-to-evaluate-the-safety-tolerability-and-efficacy-of-brodalumab-amg-827-in-subjects-with-rheumatoid-arthritis-and-an-inadequate-r/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology